TORONTO, April 9 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX:
ARI), a biotechnology company discovering and developing the next wave of
antibody therapeutics, Annual and Special Meeting of Shareholders will be
Where: St. Andrew's Club & Conference Centre, S7 Caledonia Room,
150 King Street West, 27th Floor, Toronto, Ontario
When: Thursday, April 10th, 2008 at 10:00 a.m.
Webcast: ARIUS Research Inc.'s Annual and Special Meeting will be webcast
in real time. The webcast can be viewed online starting at
10:00 a.m. at http://www.ariusmabs.com, and will be archived for 12
ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com.
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from
any future results, performance or achievements expressed or implied by
such statements. Forward-looking statements in this release include, but
are not limited to, ARIUS successfully adv
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved